tbuckley/cabot-search huggingface dataset:
Facial skin care management in cancer patients with pre-existing rosacea.
Authors: D. P. West, A. C. Haley, M. Agulnik, C. Calahan, M. Gandhi, A. Rademaker, M. E. Lacouture
Journal: Journal of Clinical Oncology (2010)

e19669 Background: The primary objective of this study is to evaluate tolerability of 2 test articles specifically developed for facial skin care during cancer treatment (face moisturizer and face wash) in patients reporting pre-existing rosacea. Methods: Participants in this study were diagnosed cancer patients with reported pre-existing rosacea (n = 12) receiving systemic anticancer therapies and/or radiotherapy at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Subjects were assessed at the initial visit for adverse skin reactions based on NCI-CTCAEv3.0 criteria and completed the Skindex-16 questionnaire, a self-reported dermatology-specific Quality of Life instrument. All subjects were provided with two test articles specifically formulated for facial skin care management: facial moisturizer and face wash, and were instructed to use each product once daily for one month. At the 4 week follow-up interview, Skindex-16 was re-administered, tolerability questionnaires were administered for each test article used, and adverse skin reactions were assessed according to NCI- CTCAE v3.0 criteria. Results: Of the 12 subjects with pre-existing rosacea, 11 subjects indicated that the facial moisturizer was very good or good (92%, 95% CI 73%-98%). A majority of subjects (9/12 or 75%) indicated the face wash was very good or good (95% CI 51%-91%). Fisher's exact test to compare tolerability by patients for both test articles was similarly acceptable (p = 0.59). Conclusions: Patients with rosacea and rosacea-like erythematous facial skin are often very sensitive to skin care products that worsen inflammation and exaggerate irritation. This study demonstrates that cancer patients with pre-existing rosacea can well-tolerate a facial moisturizer and a face wash designed specifically for cancer skin care management. In summary, specifically tailored cancer skin care management is well-tolerated by a majority of patients with pre-existing rosacea currently undergoing anticancer therapy and/or radiotherapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech, ImClone Systems, Onyx Amgen, Bayer, Bristol-Myers Squibb, ImClone Systems, Onyx Hana Biosciences
HLA Genetic Risk Burden in Multiple Sclerosis—Reply
Authors: Noriko Isobe, Jorge R. Oksenberg, Roland G. Henry
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Authors: Henrik Oster, Etienne Challet, Volker Ott, Emanuela Arvat, E. Ronald de Kloet, Derk-Jan Dijk, Stafford Lightman, Alexandros Vgontzas, Eve Van Cauter
Journal: Endocrine Reviews (2016)

Abstract Adrenal glucocorticoids are major modulators of multiple functions, including energy metabolism, stress responses, immunity, and cognition. The endogenous secretion of glucocorticoids is normally characterized by a prominent and robust circadian (around 24 hours) oscillation, with a daily peak around the time of the habitual sleep-wake transition and minimal levels in the evening and early part of the night. It has long been recognized that this 24-hour rhythm partly reflects the activity of a master circadian pacemaker located in the suprachiasmatic nucleus of the hypothalamus. In the past decade, secondary circadian clocks based on the same molecular machinery as the central master pacemaker were found in other brain areas as well as in most peripheral tissues, including the adrenal glands. Evidence is rapidly accumulating to indicate that misalignment between central and peripheral clocks has a host of adverse effects. The robust rhythm in circulating glucocorticoid levels has been recognized as a major internal synchronizer of the circadian system. The present review examines the scientific foundation of these novel advances and their implications for health and disease prevention and treatment.
Abstract A47: miR-30c: a TGF beta-regulated miRNA that coordinates vascular-directed fibrinolysis and tumor angiogenesis
Authors: James V. McCann, Lin Xiao, Omar Khan, Piotr Kowalski, Salma Azam, Chad V. Pecot, Daniel G. Anderson, Andrew C. Dudley
Journal: Cancer Research (2016)

Abstract Tumor-associated endothelial cells (TECs) are dysfunctional and leak fibrin which is resolved (fibrinolysis) and replaced with collagen in a process that closely resembles wound healing. Because degraded perivascular fibrin also promotes angiogenesis and creates scaffolds for invasive cancer cells, vascular-directed fibrinolysis in solid tumors is a fundamental spark during tumor progression. Using a miRNA screen of freshly isolated TECs, we identified a TGF beta-regulated miRNA that controls vascular-mediated fibrinolysis in tumors. miR-30c is increased in TECs relative to normal endothelial cells (NECs) whereas its target PAI-1 (a fibrinolysis inhibitor) is strikingly decreased. TECs secrete less PAI-1 and they rapidly degrade and migrate through fibrin scaffolds resulting in uncoordinated vessel sprouting. However, TGF beta and miR-30c antagomiRs reduce miR-30c expression which re-instates PAI-1 secretion, diminishes vascular-specific fibrinolysis, and “normalizes” TEC sprouting. miR-30c antagomiRs coupled to vascular-tropic nanoparticles reduce TEC migration in fibrin and enforce vascular expression of PAI-1 in vitro and in vivo. Thus, vascular-specific expression of miR-30c in tumors may be manipulated in vivo using this nanoparticle-based strategy. We also show that TGF beta promotes the export of miR-30c in extracellular vesicles (EVs) which are received by recipient stromal cells. TGF beta-mediated extravascular mobilization of miR-30c may down regulate PAI-1 expression in nearby stromal cells or cancer cells thereby programing fibrinolysis in these non-vascular recipients. Taken together, we propose an axis between TGF beta, miR-30c, and PAI-1 in TECs controls the rate of perivascular fibrinolysis and is therefore an important effector of tumor emergence. Citation Format: James V. McCann, Lin Xiao, Omar Khan, Piotr Kowalski, Salma Azam, Chad V. Pecot, Daniel G. Anderson, Andrew C. Dudley. miR-30c: a TGF beta-regulated miRNA that coordinates vascular-directed fibrinolysis and tumor angiogenesis. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr A47.
Deutetrabenazine—Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease
Authors: Ralf Reilmann
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
Authors: Tushar Tomar, Steven de Jong, Nicolette G. Alkema, Rieks L. Hoekman, Gert Jan Meersma, Harry G. Klip, Ate GJ van der Zee, G. Bea A. Wisman
Journal: Genome Medicine (2016)

In high-grade serous ovarian cancer (HGSOC), intrinsic and/or acquired resistance against platinum-containing chemotherapy is a major obstacle for successful treatment. A low frequency of somatic mutations but frequent epigenetic alterations, including DNA methylation in HGSOC tumors, presents the cancer epigenome as a relevant target for innovative therapy. Patient-derived xenografts (PDXs) supposedly are good preclinical models for identifying novel drug targets. However, the representativeness of global methylation status of HGSOC PDXs compared to their original tumors has not been evaluated so far. Aims of this study were to explore how representative HGSOC PDXs are of their corresponding patient tumor methylome and to evaluate the effect of epigenetic therapy and cisplatin on putative epigenetically regulated genes and their related pathways in PDXs. Genome-wide analysis of the DNA methylome of HGSOC patients with their corresponding PDXs, from different generations, was performed using Infinium 450 K methylation arrays. Furthermore, we analyzed global methylome changes after treatment of HGSOC PDXs with the FDA approved demethylating agent decitabine and cisplatin. Findings were validated by bisulfite pyrosequencing with subsequent pathway analysis. Publicly available datasets comprising HGSOC patients were used to analyze the prognostic value of the identified genes. Only 0.6–1.0 % of all analyzed CpGs (388,696 CpGs) changed significantly (p < 0.01) during propagation, showing that HGSOC PDXs were epigenetically stable. Treatment of F3 PDXs with decitabine caused a significant reduction in methylation in 10.6 % of CpG sites in comparison to untreated PDXs (p < 0.01, false discovery rate <10 %). Cisplatin treatment had a marginal effect on the PDX methylome. Pathway analysis of decitabine-treated PDX tumors revealed several putative epigenetically regulated pathways (e.g., the Src family kinase pathway). In particular, the C-terminal Src kinase (CSK) gene was successfully validated for epigenetic regulation in different PDX models and ovarian cancer cell lines. Low CSK methylation and high CSK expression were both significantly associated (p < 0.05) with improved progression-free survival and overall survival in HGSOC patients. HGSOC PDXs resemble the global epigenome of patients over many generations and can be modulated by epigenetic drugs. Novel epigenetically regulated genes such as CSK and related pathways were identified in HGSOC. Our observations encourage future application of PDXs for cancer epigenome studies.
Lentiviral FANCA Vectors Pseudotyped with a Modified Prototype Foamy Viral Envelope Corrects Murine Fanca−/− Hematopoietic Stem Cells with Reduced Toxicity.
Authors: Zejin Sun, Yanzhu Yang, Yan Li, Daisy Zeng, Jingling Li, Dirk Lindemann, D. Wade Clapp, Helmut Hanenberg
Journal: Blood (2007)
Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia
Authors: Anna Hecht, Daniel Nowak, Florian Nolte, Verena Nowak, Julia Oblaender, Thomas Buechner, Karsten Spiekermann, Wolf-Karsten Hofmann, Eva Lengfelder
Journal: Blood (2015)
Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23
Authors: Amanda McGovern, Stefan Schoenfelder, Paul Martin, Jonathan Massey, Kate Duffus, Darren Plant, Annie Yarwood, Arthur G. Pratt, Amy E. Anderson, John D. Isaacs, Julie Diboll, Nishanthi Thalayasingam, Caroline Ospelt, Anne Barton, Jane Worthington, Peter Fraser, Stephen Eyre, Gisela Orozco
Journal: Genome biology (2016)

The identification of causal genes from genome-wide association studies (GWAS) is the next important step for the translation of genetic findings into biologically meaningful mechanisms of disease and potential therapeutic targets. Using novel chromatin interaction detection techniques and allele specific assays in T and B cell lines, we provide compelling evidence that redefines causal genes at the 6q23 locus, one of the most important loci that confers autoimmunity risk.Although the function of disease-associated non-coding single nucleotide polymorphisms (SNPs) at 6q23 is unknown, the association is generally assigned to TNFAIP3, the closest gene. However, the DNA fragment containing the associated SNPs interacts through chromatin looping not only with TNFAIP3, but also with IL20RA, located 680 kb upstream. The risk allele of the most likely causal SNP, rs6927172, is correlated with both a higher frequency of interactions and increased expression of IL20RA, along with a stronger binding of both the NFκB transcription factor and chromatin marks characteristic of active enhancers in T-cells.Our results highlight the importance of gene assignment for translating GWAS findings into biologically meaningful mechanisms of disease and potential therapeutic targets; indeed, monoclonal antibody therapy targeting IL-20 is effective in the treatment of rheumatoid arthritis and psoriasis, both with strong GWAS associations to this region.
Prevalence and Prognostic Impact of KIT Mutations in Acute Myeloid Leukaemia with Inv(16). A Retrospective Study.
Authors: Roberto Cairoli, Alessandro Beghini, Carla B. Ripamonti, Giovanni Grillo, Gianpaolo Nadali, Enrico Di Bona, Patrizia Colapietro, Michele Nichelatti, Gianbattista Bertani, Erika Ravelli, Antonio Cuneo, Emanuela Ottaviani, Pietro Pioltelli, Felicetto Ferrara, Mario Lazzarino, Giuseppe Rossi, Francesco Rodeghiero, Giovanni Pizzolo, Giovanni N. Martinelli, Enrica Morra
Journal: Blood (2007)
10-Year-Outcome of Acquired Aplastic Anemia Children Treated with Antithymocyte Globulin, Cyclosporine with or without G-CSF.
Authors: Akira Ohara, Seiji Kojima, Ryoji Kobayashi, Yoshiyuki Kosaka, Shoichi Ohga, Kanji Sugita, Hiromasa Yabe, Masahiro Tsuchida, Fumio Bessho, Hideo Mugishima, Ichiro Tsukimoto, Tatsutoshi Nakahata
Journal: Blood (2006)
Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).
Authors: Michael J. Hall, Kyle Gowen, Eric M. Sanford, Julia Andrea Elvin, Siraj Mahamed Ali, John Kaczmar, Emily White, Christine Malboeuf, Jeffrey S. Ross, Vincent A. Miller, Phil Stephens, Roman Yelensky, Mary Beryl Daly, James Sun
Journal: Journal of Clinical Oncology (2016)

1523 Background: MSI status is predictive of anti-PD-1/L1 therapy efficacy independent of tumor histology. This study describes the development and validation of a novel computational method to assess MSI status. In addition, we sought to determine the MSI prevalence and mutation characteristics in the cohort by applying the method to 11,573 clinical solid tumor cases previously assayed with CGP. Methods: To determine MSI status, 114 intronic homopolymer repeat loci with adequate coverage on the CGP panel were analyzed for length variability and compiled into an overall MSI score via principal components analysis. Translation of the MSI score to MSI-H (microsatellite high) or MSS (microsatellite stable) was established using training data. A matched-normal sample is not required, and CGP is accurate when tumor content is at least 20%. Results: Our methodology was validated in 69 samples with MSI status (20 MSI-H, 49 MSS) previously determined by standard clinical testing (PCR or immunohistochemistry). Concordance was 97% (65/67). 161/11,573 (1.4%) assayed tumors were MSI-H, with uterine cancer having the highest frequency (Table). Differences in mutational profile were consistent across tumor types: histone methyltransferase MLL2/3 and chromatin remodeling ARID1A mutations were enriched in MSI-H, while TP53 mutations were depleted (p < 0.0001, Fisher's Exact). Conclusions: CGP detects MSI with high accuracy. Application of these methods to this large sample demonstrates the utility of CGP in identifying differences in mutational profiles between MSI-H and MSS cancers. Use of these methods across solid tumors may provide a powerful enrichment strategy for emerging immunotherapies. MSI-H across tumor types. Tumor type MSI-H rate (%) Sample size Mutations enriched in MSI-H Mutations enriched in MSS Uterine 14.1 39/277 PTEN, ARID1A, PIK3CA, MLL2 TP53 Small bowel 8.6 6/70 Prostate 6.2 11/178 Colorectal 3.5 42/1185 MLL2/3, ARID1A TP53, APC, KRAS Cancer of unknown primary 2.7 22/815 MLL2/3, ARID1A Hepatobiliary 2.3 9/389 Gastroesophageal 1.5 6/400 Neuroendocrine 0.2 1/431 Pancreas 0.2 1/459 NSCLC 0.2 5/2112 Breast 0.1 2/1459
Rescue with Rituximab ® Monotherapy in Resistant T - Cell Rich B - Cell Lymphoma (TCRBCL).
Authors: Ruben A. Burgos, Isabel A. Hanono, Maria C. Foncuberta, Enzo Domenichini, Eduardo Huertas, Julio C. Sanchez Avalos, Norma E. Tartas
Journal: Blood (2005)
Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders
Authors: Neha Korde, Sham Mailankody, Evgeny Arons, Raul C. Braylan, Mark Raffeld, Elizabeth Maestri, Constance Yuan, Maryalice Stetler-Stevenson, Ola Landgren, Irina Maric, Robert J. Kreitman
Journal: Blood (2014)
Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
Authors: Mengxuan Tang, Davis C Ryman, Eric McDade, Mateusz S Jasielec, Virginia D Buckles, Nigel J Cairns, Anne M Fagan, Alison Goate, Daniel S Marcus, Chengjie Xiong, Ricardo F Allegri, Jasmeer P Chhatwal, Adrian Danek, Martin R Farlow, Nick C Fox, Bernardino Ghetti, Neill R Graff-Radford, Christopher Laske, Ralph N Martins, Colin L Masters, Richard P Mayeux, John M Ringman, Martin N Rossor, Stephen P Salloway, Peter R Schofield, John C Morris, Randall J Bateman
Journal: The Lancet Neurology (2016)
Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,
Authors: Etan Orgel, Richard Sposto, Jemily Malvar, Nita L. Seibel, Elena J. Ladas, Paul Gaynon, David R. Freyer
Journal: Blood (2011)
GW26-e2300 Gender differences in clinical characteristics and inpatient outcomes amongst 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Registry
Authors: Qinmei Xiong, Alena Shantsila, Qiongqiong Zhou, Ying Liu, Yang Shen, Deirdre Lane, Xiaoshu Cheng, Kui Hong, Gregory YH Lip
Journal: Journal of the American College of Cardiology (2015)
GW26-e2201 Recombinant adeno-associated virus serotype 9 transfection of atherosclerosis mice: determination of the optimal expression time in vivo
Authors: Jia Xie, Yining Yang, Xiaomei Li, Bangdang Chen, Fen Liu, Qingjie Chen, Hui Zhai, Yiyong Ma
Journal: Journal of the American College of Cardiology (2015)
Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.
Authors: Miguel Alcoceba, Elena Sebastián, Luis Marín, Ana Balanzategui, M. Dolores Caballero, Eva González-Barca, Emilia Pardal, Alejandro Martin, Carlos Grande, José Luis Bello, Carmen Albo, Fatima de la Cruz, Carlos Panizo, Eulogio Conde, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Noemí Puig, Rocío Corral, Jesús F. San Miguel, Ramón García-Sanz, Marcos González
Journal: Blood (2012)
Gemcitabine/cisplatin in patients with advanced bladder and impaired renal function: A retrospective analysis.
Authors: R. Morales, C. Serrano, J. Bellmunt, B. Mellado, M. Guix, M. Gallen, A. Font, C. Suarez, C. M. Valverde, J. Carles
Journal: Journal of Clinical Oncology (2011)

274 Background: A four-weekly regimen of gemcitabine and cisplatin (GEMCIS) has similar activity and is less toxic than MVAC in advanced bladder cancer. However, full-dose cisplatin in unfit patients with impaired renal function is contraindicated and other carboplatin-based schedules have been developed. We have previously reported the feasibility of GEMCIS in a biweekly schedule in unfit patients with renal impairment. Here we report a multicenter retrospective study of this biweekly regimen in patients with impaired renal function. Methods: Between January 2004 and October 2009, 40 patients with locally advanced nonsurgically resectable or metastatic bladder cancer and impaired renal function were included. Treatment consisted of gemcitabine 2500 mg/m 2 on day 1 and cisplatin 35 mg/m 2 on day 1, every 14 days. Results: Median age of the patients was 73 years (range: 51-82 years). Median IK was 80% (range: 60-100%). Mean creatinine clearance was 49 ml/min (range:37-59 ml/min). Eight patients had previously received chemotherapy with gemcitabine and/or platinum based therapy. Metastatic localizations were: 17 lymph nodes, 10 pulmonary, 10 bone, 7 liver, 12 pelvic and 1 central nervous system. The median number of cycles/patient was 6 (1-13). Out of 36 patients evaluable for response, there was one complete response, 14 partial responses (ORR: 42%; 95% CI 27-58%), 11 stabilizations and 10 progressive diseases. Hematologic toxicities were grade 1 anaemia in 15 patients, grade 2 in 8; grade 3 in 2; grade 3 neutropenia in 5 patients and grade 4 in 1 patient; grade 3 plaquetopenia in 3 patients. Nonhematologic toxicities were grade 1-2 vomiting in 2 patients. Two patients showed a grade 2 hepatic toxicity. Worsening of the renal function was observed in two patients. Alopecia grade 1-2 was seen in three patients. There was one toxic death related to metabolic acidosis.The median progression-free survival is 15 weeks. The median OS from first cycle of GEMCIS is 35 weeks and 1-year OS is 43% (St error 9%). Conclusions: A two-weekly schedule of gemcitabine plus cisplatin is feasible, active, and generally well tolerated in an outpatient setting in unfit patients with poor renal reserve. No significant financial relationships to disclose.
Human Endothelial Cells Generated In Vitro from Circulating Progenitors Represent a Safe Tool for Targeting of Myocardial Tissue.
Authors: Ruth Koeck, Dominik G.F. Wolf, Holger F. Rumpold, Harald Ott, Gerold Untergasser, Martin Erdel, Paul Debagge, Guenther A. Gastl, Eberhard Gunslius
Journal: Blood (2004)